American Skin Association (ASA)  
Mulvaney Family Foundation Research Grant  
for Vitiligo/Pigment Cell Disorders  
$15,000

American Skin Association (ASA) is accepting applications for support of research in vitiligo/pigment cell disorders.

ELIGIBILITY:
Applicants must be working actively in areas related to dermatology and vitiligo/pigment cell disorders. Funds may be used for support of a new or ongoing research/clinical investigation project. There is no age requirement. However, applicants without prior funding, who are in a formative stage of their career, or who are undergoing a mid-career research change, will be given preference.

CONTENTS OF APPLICATION:
An application must include:
1. A letter from the applicant with sections labeled in the following order:
   a. a lay statement of 2-3 sentences describing the relevance of the proposed research
   b. how would this grant impact and help you achieve your career goals
   c. acknowledgment of the requirement to submit a progress report (written for a layperson) and an expenditure report at six months and at the end of the award period
   d. acknowledgement of the requirement to list ASA support in all presentations/publications
   e. acknowledgement to keep ASA informed of current and future dates of presentations and/or publications
2. 1-2 page curriculum vitae including education and training, academic appointments, key publications, and date of birth.
3. A letter (no more than two pages) written by the Chair of Dermatology on behalf of the candidate, endorsing the applicant and the proposal, and confirming the institution’s commitment to provide time and support to the applicant.
   Note: A Chair may endorse only ONE Research Grant application in each area per year.
4. A research proposal (no more than two pages including references) prepared by the candidate detailing the title, purpose, materials, methods and projected results. Proposals must be typed in Arial 11 pt. type with 1-inch margins.
   Note: Human and/or animal use must be approved by the Institutional Review Board or equivalent and documented before funding is provided.
5. A timeline for accomplishing specific aims.
6. A line item budget and justification for the research project must be attached. Tuition, salary, travel expenses, and indirect costs to the sponsoring institution are not permitted.
7. A summary of ALL past (5 years), current, and pending applications for research support, specifying grant titles, agencies, periods of support, and total direct costs. Please provide total amount of current funding for the period May 1, 2023 – April 30, 2024. If none, please indicate.

All sources of funding must be disclosed by the applicant. We recognize that the PI may need more than one source of funding to move their research forward. If the PI has other research support, they must justify why the additional support from the ASA is needed. If the ASA award and the other award significantly overlap in budget, the awardee must choose between it and this research award. If the other award is pending and subsequently chosen, the applicant must inform the ASA immediately to determine if any remaining installments of funding from ASA are forfeited.

DEADLINE AND APPLICATION FORMS:
Instructions and the online application are posted on our website: americanskin.org. The deadline for receipt of applications is Tuesday, February 7, 2023 at 11:59 PM EST. Incomplete applications will not be considered.

SELECTION PROCESS:
Selection of the recipients will be made in April 2023 by ASA’s Medical Advisory Committee. Funding will begin in 2023.
Please note: No-cost extensions will not be granted.

About American Skin Association
Established to serve the now more than 100 million Americans afflicted with skin disorders, ASA has evolved over the past three decades as a leading force in efforts to defeat melanoma and other serious forms of skin disease. Its mission has remained to advance research, champion skin health, and drive public awareness about skin disease.

Please send questions to grants@americanskin.org.